@article{721ce76eedad4e91bd359dee70966c67,
title = "The clinician{\textquoteright}s guide to randomized trials: interpretation",
keywords = "Humans, Randomized Controlled Trials as Topic",
author = "\{for the Retina Evidence Trials InterNational Alliance (R.E.T.I.N.A.) Study Group\} and Alex Thabane and Phillips, \{Mark R.\} and Wong, \{Tien Y.\} and Lehana Thabane and Mohit Bhandari and Varun Chaudhary and Wykoff, \{Charles C.\} and Sobha Sivaprasad and Peter Kaiser and David Sarraf and Sophie Bakri and Garg, \{Sunir J.\} and Singh, \{Rishi P.\} and Holz, \{Frank G.\} and Guymer, \{Robyn H.\}",
note = "Funding Information: T.Y.W. is the Advisory Board Member and receive financial support from Allergan, Bayer, Boehringer-Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche, Samsung Bioepis, Novartis Singapore; Co-founder of Plano, EyRiS. M.B. receive research funds from Pendopharm, Bioventus, Acumed – unrelated to this study. V.C. is the Advisory Board Member of Alcon, Roche, Bayer, Novartis; receive grants from Bayer, Novartis – unrelated to this study. A.T., M.R.P. and L.T. declare no competing interests. ",
year = "2022",
month = mar,
doi = "10.1038/s41433-021-01866-7",
language = "English (US)",
volume = "36",
pages = "481--482",
journal = "Eye (Basingstoke)",
issn = "0950-222X",
publisher = "Springer Nature",
number = "3",
}